A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

Start Date08 May 2026

Sponsor / Collaborator

ViiV Healthcare Ltd.

CTR20253858

/ CompletedNot Applicable

拉米夫定多替拉韦片（300mg/50mg）在健康受试者中随机、开放、两制剂、单次给药、两周期、两序列餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-dose, single-dose, two-cycle, two-sequence fed bioequivalence study of lamivudine-dolutegravir tablets (300 mg/50 mg) in healthy volunteers

主要目的：以海南林依生物科技有限公司的拉米夫定多替拉韦片（规格：拉米夫定300mg/多替拉韦钠50mg（以多替拉韦计））为受试制剂，按生物等效性试验的有关规定，与持证商ViiV Healthcare BV公司的拉米夫定多替拉韦片（规格：拉米夫定300mg/多替拉韦钠50mg（以多替拉韦计），商品名：多伟托®）对比餐后状态下在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察餐后状态下受试制剂拉米夫定多替拉韦片（300mg/50mg）和参比制剂拉米夫定多替拉韦片（300mg/50mg）（商品名：多伟托®）在健康受试者中的安全性。

[Translation]

Primary Objective: Using Hainan Linyi Biotechnology Co., Ltd.'s Lamivudine-Dolutegravir Tablets (strength: lamivudine 300 mg/dolutegravir sodium 50 mg (calculated as dolutegravir)) as the test formulation, and comparing their absorption rate and extent in healthy volunteers with the Lamivudine-Dolutegravir Tablets (strength: lamivudine 300 mg/dolutegravir sodium 50 mg (calculated as dolutegravir)) from the licensed supplier, ViiV Healthcare BV (trade name: Duoweito®), in accordance with relevant bioequivalence regulations, the authors investigated the bioequivalence of the two formulations in healthy volunteers following a fed state. Secondary Objective: To investigate the safety of the test formulation, Lamivudine-Dolutegravir Tablets (300 mg/50 mg), and the reference formulation, Lamivudine-Dolutegravir Tablets (300 mg/50 mg) (trade name: Duoweito®), in healthy volunteers following a fed state.

Start Date29 Sep 2025

Sponsor / Collaborator

Hai Nan Lin Yi Sheng Wu Ke Ji You Xian Gong Si

NCT06497465

/ RecruitingPhase 3IIT

Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment

This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice daily or DTG/3TC ( Dovato) in the morning +dolutegravir (DTG) in the evening, versus standard of care (SOC) twice-daily dolutegravir plus 2 once-daily Nucleoside reverse-transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate /lamivudine (TDF/3TC), among antiretroviral therapy (ART)-nave individuals with HIV-1 receiving rifampin-based TB therapy

Start Date18 Sep 2025

Sponsor / Collaborator

The Johns Hopkins University

[+1]

100 Clinical Results associated with Dolutegravir Sodium/Lamivudine

100 Translational Medicine associated with Dolutegravir Sodium/Lamivudine

100 Patents (Medical) associated with Dolutegravir Sodium/Lamivudine

Literatures (Medical) associated with Dolutegravir Sodium/Lamivudine

01 Oct 2025·Therapeutic Advances in Infectious Disease

Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study

Article

Author: Marcellin, Fabienne ; Brown Hajdukova, Eva ; Chassany, Olivier ; Alain, Tristan ; Duracinsky, Martin ; Hocqueloux, Laurent ; Rousset Torrente, Olivia ; Zucman, David ; Allavena, Clotilde

Background::

Simplification of antiretroviral regimens has the potential to improve both patient-reported outcomes (PROs) and therapeutic adherence in people living with HIV (PLWH). Dual therapy with dolutegravir (DTG) plus lamivudine (3TC) demonstrated good safety and efficacy, but its impact on PROs remains to be documented.

Objectives::

To evaluate PROs among adult PLWH switching from standard multi-drug therapy to the DTG/3TC combined therapy Dovato ® .

Design::

A non-comparative, 6-month observational study in 25 French medical centers.

Methods::

Sociodemographic and biomedical data were collected from medical records and PROs from self-administered questionnaires at treatment switch (Day, D0) and at months (M) 1 and 6. Primary endpoints included changes between D0 and M6 in perceived toxicity, treatment acceptability, PLWH’s preferences, and the score value of the treatment impact dimension of health-related quality of life (HRQL) (PROQOL-HIV) during follow-up. Secondary endpoints encompassed scores in other HRQL dimensions and self-reported symptoms. Multivariable standard and mixed-effects linear regression models were used to identify factors associated with PRO values and changes over time. Additionally, binary logistic regression was used to identify factors associated with the discontinuation of combined DTG/3TC regimen.

Results::

In the study population (260 PLWH, 64.6% male, mean ± SD age: 51 ± 12 years, 16 ± 10 years since HIV diagnosis), 20 individuals stopped treatment during follow-up, without resumption. Men, individuals previously receiving abacavir/3TC/DTG, and those with better daily comfort and perceived treatment efficacy were less likely to stop treatment. Treatment impact-related HRQL, acceptability of treatment, and number of self-reported symptoms significantly improved at M1 and M6. Mental and cognitive HRQL improved at M6.

Conclusion::

Dolutegravir and lamivudine dual oral therapy improved several dimensions in HRQL and delivered a simplified treatment regimen designed for eligible patients, supporting a patient-centered approach to managing HIV care. Attention should be maintained on the reasons for treatment discontinuation, especially among women.

Trial registration::

Patient-Reported Outcomes HV BItherapy (PROBI) was registered as number NCT04788784 on https://clinicaltrials.gov/study/NCT04788784?term=PROBI&rank=2 .

21 Apr 2025·Cureus Journal of Medical Science

A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort

Article

Author: Fallon, James P ; Borsi, Rebecca A ; Touza, Masara ; Slim, Jihad ; Bellafiore, Paul

OBJECTIVE:

This article aims to examine the safety and efficacy of switching from bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) to dolutegravir and lamivudine (DTG/3TC) in the absence of prior resistance records.

DESIGN:

Switch to Dovato in patients suppressed on Biktarvy (SOUND) is an open-label, single-arm, pilot study of adult people with HIV who were virologically suppressed (HIV-1 <50 copies/mL) on B/FTC/TAF for >24 weeks, and switched to DTG/3TC in the absence of available resistance records.

METHODS:

The primary endpoint was the percentage of participants with HIV viral load (VL) ≥50 c/mL at week 48. Secondary endpoints at weeks 48 and 96 included the percentage of participants with HIV-VL <50 c/mL, incidence and severity of adverse events, laboratory abnormalities, change in baseline CD4 cell count, and retrospective proviral DNA resistance testing on banked baseline samples.

RESULTS:

Of the 40 individuals enrolled, 0% had VL ≥50 c/mL at week 48. No participants discontinued due to laboratory abnormalities or safety-related concerns. Three participants withdrew from the study while virologically suppressed. Among the 32 baseline samples available for retrospective proviral DNA resistance testing, six (19%) had nucleoside reverse transcriptase inhibitor resistance-associated mutations (RAMs), all with M184V. Two (6%) participants had integrase strand transfer inhibitor RAMs at baseline (S147S/G and Q148Q/R); neither conferred resistance to DTG. Nonnucleoside reverse transcriptase inhibitor and protease inhibitor RAMs were observed in eight (25%) and three (9%) participants, respectively. A significant decrease in weight was observed over the study period.

CONCLUSIONS:

Results from SOUND support the efficacy and safety of switching to DTG/3TC for people living with HIV-1 who are virologically suppressed on B/FTC/TAF with unknown resistance history and may confer a weight advantage.

02 May 2024·Antimicrobial agents and chemotherapy

Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1

Article

Author: Pene Dumitrescu, Teodora ; Singh, Rajendra ; Ait-Khaled, Mounir ; Adkison, Kimberly ; Chandasana, Hardik

ABSTRACT:

A fixed-dose combination (FDC) of 50 mg dolutegravir and 300 mg lamivudine is indicated for the treatment of HIV-1 infection. This analysis aimed to characterize the population pharmacokinetics (PK) of dolutegravir and lamivudine based on data from a phase 3 study (TANGO) in virologically suppressed adults living with HIV-1 switching to dolutegravir/lamivudine FDC. These analyses included 362 participants who contributed 2,629 dolutegravir and 2,611 lamivudine samples collected over 48 weeks. A one-compartment model with first-order absorption and elimination parameterized by apparent oral clearance (CL/F), apparent volume of distribution (V/F), and absorption rate constant (Ka) described dolutegravir PK. Covariate search yielded body weight, bilirubin, and ethnicity as predictors of CL/F, and weight was predictive for V/F. The estimates of CL/F, V/F, and Ka were 0.858 L/h, 16.7 L, and 2.15 h −1 , respectively. A two-compartment model with first-order absorption and elimination parameterized by CL/F, apparent intercompartmental clearance (Q/F), apparent central volume of distribution (V2/F), apparent peripheral volume of distribution (V3/F), and Ka described lamivudine PK. Covariate search yielded eGFR and race as predictors of CL/F, and weight was predictive for V2/F. The estimated parameter values were CL/F = 19.6 L/h, Q/F = 2.97 L/h, V2/F = V3/F = 105 L, and Ka = 2.30 h −1 . The steady-state prediction suggested that the effect of covariates dolutegravir and lamivudine exposures was small (<20%) and not clinically relevant. Therefore, no dose adjustments are recommended based on these analyses. The results support the use of dolutegravir/lamivudine FDC in the treatment of HIV-1 infection in adults.

CLINICAL TRIALS:

This study is registered with ClinicalTrials.gov as NCT03446573 .

News (Medical) associated with Dolutegravir Sodium/Lamivudine

23 Feb 2026

·viivhealthcare.com

ViiV HEALTHCARE ANNOUNCES DATA SHOWING SWITCHING TO DOVATO WAS ASSOCIATED WITH A LOWER PROPORTION OF STEATOTIC LIVER DISEASE VERSUS BIKTARVY FOR HIV-1 TREATMENT

96-week data from a sub-group analysis of the head‑to‑head PASO DOBLE study build on earlier metabolic findings supporting 2-drug Dovato (dolutegravir/lamivudine (DTG/3TC)) versus 3-drug regimen Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in adults living with HIV who are virologically suppressed Steatotic liver disease, an increasingly recognised comorbidity in people living with HIV, was reported in 49% (n=26/53) of participants switching to BIC/FTC/TAF versus 29% (n=17/58) switching to DTG/3TC London, 23 February 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced 96-week data from a sub-group analysis of PASO DOBLE (GeSIDA 11720), showing that switching to Dovato (dolutegravir/lamivudine (DTG/3TC)) was associated with a lower proportion of steatotic liver disease (SLD) compared to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in adults living with HIV-1 who are virologically suppressed.1 Results were presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado. PASO DOBLE is the largest head-to-head, phase IV randomised clinical trial investigating the 2‑drug regimen DTG/3TC compared with the 3‑drug regimen BIC/FTC/TAF for the treatment of HIV-1 in virologically suppressed adults. This planned sub-analysis at 96 weeks focused on SLD, an increasingly recognised comorbidity linked to metabolic health and weight gain in people living with HIV. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “ViiV Healthcare has led innovation in HIV by developing effective regimens containing fewer medicines. This 96-week PASO DOBLE sub-analysis adds to the robust clinical and real-world data for Dovato, showing differences between the 2‑drug regimen DTG/3TC and BIC/FTC/TAF as a 3‑drug regimen in metabolic health outcomes. These findings allow healthcare providers and people living with HIV to make informed choices regarding long-term HIV treatment, including considerations around impact on metabolic health.” The 96‑week SLD sub‑study of PASO DOBLE included 111 adults living with HIV who were virologically suppressed and who switched to either DTG/3TC (n=58) or BIC/FTC/TAF (n=53). At Week 96, SLD was observed in 49% (n=26/53) of participants on BIC/FTC/TAF compared with 29% (n=17/58) on DTG/3TC (p=0.033). The difference was most pronounced in those with clinically meaningful weight gain (≥5% of baseline body weight), where SLD was reported in 76% (n=13/17) of participants on BIC/FTC/TAF vs. 17% (n=2/12) on DTG/3TC (p=0.002). No significant change was seen in those who gained <5% of their baseline body weight. After adjusting for relevant baseline factors, treatment regimen remained independently associated with steatotic liver disease. Previous 96-week results from the PASO DOBLE study showed that switching to DTG/3TC was associated with less weight gain than switching to BIC/FTC/TAF, with a mean adjusted difference of 1.52 kg, and virologic suppression remaining non-inferior between the two treatment arms. Since SLD is closely associated with weight gain and metabolic changes, this sub‑study provides insight into weight and liver steatosis outcomes when switching to BIC/FTC/TAF compared with switching to DTG/3TC. About Dovato (dolutegravir and lamivudine) Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25 kg in the US, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. Please consult the full Prescribing Information here. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q4 Results for 2025. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY *On 20 January 2026, GSK plc and Shionogi & Co., Ltd announced that they have reached agreement together with Pfizer Inc. for the economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026. References: ViiV Press Releases & Company Statements For our corporate press office, email: Rachel Jaikaran OR call +44 7823 523 755 For US-specific media enquiries, email: melinda.x.stubbee@viivhealthcare.com OR call +1 919 491 0831 Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine. If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here. Connect with us ViiV Healthcare 79 New Oxford Street London United Kingdom WC1A 1DG Tel: +44 20 8047 5000 Contact us Terms of use Cookie policy Privacy notice Modern Slavery Statement Sitemap All our locations Our Clinical Trial Register GSK.com Carbon Reduction Plan Corporate ethics and compliance Social Media at ViiV Healthcare

Clinical ResultPhase 3

17 Feb 2026

·www.biospace.com

ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ultra long-acting pipeline 12-month data to be presented for investigational lotivibart (N6LS) + cabotegravir long-acting, evaluating feasibility of ultra long-acting dosing intervals Clinical data and real-world evidence from ViiV’s innovative portfolio include insights for established INSTI-based long-acting Cabenuva (cabotegravir + rilpivirine LA) and 2-drug regimen Dovato (dolutegravir/lamivudine) LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, * today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “We are making major advances towards new ultra long‑acting regimens that build on ViiV’s legacy of integrase inhibitors, including pipeline assets such as VH184 that have the potential to extend dosing intervals to four months or longer – beyond what is available today for HIV treatment. Listening to the needs of the HIV community shapes our research and development, and the breadth of clinical and real‑world data we are presenting at CROI 2026 reflects our commitment to delivering long‑acting therapies that people impacted by HIV need and want.” Key data to be presented at CROI 2026 by ViiV Healthcare and study partners include: Advancing the next generation of ultra long‑acting (ULA) HIV treatment candidates: For VH184, the first third-generation INSTI, data from the ongoing first-in-human phase I study of injectable long-acting formulations will provide insights into its ULA potential in future regimens, 1 while an additional analysis evaluates its in-vitro resistance pro bictegravir. 2 Additionally, an interim analysis from the phase IIb EMBRACE study will report long-term data on HIV suppression and safety at 12 months with lotivibart (N6LS), an investigational broadly neutralising antibody administered every four months, in combination with monthly long-acting cabotegravir (CAB LA) for HIV treatment. 3 Additional presentations illustrate data that will inform dosing and ULA feasibility of the injectable HIV‑1 capsid inhibitor, VH499. 4,5 Exploring longer‑interval HIV prevention with cabotegravir ULA: The phase I CAB ULA 012 study explores dose selection of cabotegravir ULA, to support administration every four months, and informs the path toward expanded prevention choices. 6 Expanding evidence across different populations for Cabenuva (cabotegravir + rilpivirine LA), the only complete long-acting injectable HIV treatment: Late-breaking results from the phase IIIb VOLITION study will provide an update on Month 11 outcomes among ART-naïve adults who chose to switch to cabotegravir + rilpivirine (CAB+RPV) LA (branded as Vocabria + Rekambys outside the US, Canada and Australia) immediately after achieving virologic suppression on once daily Dovato (dolutegravir/lamivudine (DTG/3TC)). 7 Additionally, analyses from the real-world OPERA cohort will report virologic outcomes by body mass index categories for individuals suppressed at CAB+RPV LA initiation and four-year follow-up results for individuals initiating CAB+RPV LA with viral loads ≥50 vs <50 copies/mL. 8,9 New evidence supporting CAB LA for PrEP and understanding PrEP uptake: An updated analysis from the phase I CLARITY study will provide detail on acceptability, visibility and size of injection‑site reaction nodules following single-dose lenacapavir and cabotegravir injections, supporting informed choice. 10 Data from the OPERA cohort will outline Apretude (CAB LA for PrEP) effectiveness over three years, as well as coverage vs oral PrEP in routine care, providing important insights to guide implementation and adherence support. 11,12 Twelve-month real-world effectiveness and acceptance data for CAB LA for PrEP among Black women, a group disproportionately impacted by HIV, will also be presented. 13 Strengthening evidence for dolutegravir-based treatment across populations: The first efficacy meta-analysis between DTG/3TC vs DTG three drug regimens in ART-naïve people with high or very high viral load and/or low CD4 will be presented. 14 Several analyses from PASO DOBLE, the largest head-to-head randomised clinical trial of DTG/3TC vs bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), will provide insights on the differential metabolic impact including steatotic liver disease and adipose tissue at 96 weeks. 15,16,17 Results from the SUNGURA study including safety and efficacy data in virally supressed older people living with HIV (≥60 years), switching to DTG/3TC from BIC/FTC/TAF will also be presented. 18 Advancing paediatric treatment with LA options and DTG-based regimens: Week 96 and end-of-study results for adolescents (IMPAACT 2017; MOCHA), and first safety and pharmacokinetics data for children <20 kg (IMPAACT 2036; CRAYON) – from two of our registrational supported collaborative studies – illustrate CAB+RPV LA treatment strategies in younger age groups. 19,20 Findings from an additional study from Southern Africa will describe viral suppression in children aged ≤5 years on DTG, highlighting its role in paediatric treatment. 21 Results from PENTA 21 will explore non-inferiority of the simplified oral regimen DTG/3TC vs 3-drug ART in treating children. 22 Key ViiV Healthcare sponsored or supported studies to be presented at CROI 2026: Title Presenting author Oral abstract session CAB+RPV LA Treatment Long-Acting Cabotegravir + Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results A. Gaur Oral Presentation Next-Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care 24 February 2026 DTG/3TC DTG/3TC is Non-Inferior to DTG-based 3-Drug ART in Children with HIV: D3/Penta 21 Week 96 Results A. Turkova Oral Presentation Next Generation HIV Strategies for Children and Adolescents: Breakthroughs in Pediatric HIV Prevention, Treatment, and Care 24 February 2026 Lotivibart (N6LS) Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study C.P. Rolle Oral Presentation Extending the Reach: Long-Acting Antiviral and Novel Delivery 25 February 2026 VH184 Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184 H. Back Oral Presentation Extending the Reach: Long-Acting Antiviral and Novel Delivery 25 February 2026 VH499 Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing N. Thakkar Oral Presentation Extending the Reach: Long-Acting Antiviral and Novel Delivery 25 February 2026 Title Presenting author Poster abstract session CAB+RPV LA Treatment Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION B. Jones Poster (G-04) Cabotegravir and Rilpivirine in the "Real World" 25 February 2026 Outcomes for Individuals who Initiate CAB+RPV LA in OPERA with Viral Loads ≥50 vs. <50 copies/mL R. K. Hsu Poster (G-04) Cabotegravir and Rilpivirine in the "Real World" 25 February 2026 Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort M. G. Sension Poster (G-04) Cabotegravir and Rilpivirine in the "Real World" 25 February 2026 Safety And Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Young Children 10 - <40kg M. Archary Poster (P-04) Pharmacokinetics, Safety, and Use of ARVs, Old and New, in Infants, Children, and Adolescents 24 February 2026 CAB LA for PrEP Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study E. Castronova Poster (F-02) Going the Distance: Pharmacokinetics of Next-Generation Long-Acting Agents 24 February 2026 Injection Site Reactions More Common and Bothersome with Single Doses of Lenacapavir vs Cabotegravir K. Brown Poster (S-01) Who is Using Injectable PrEP, and How's That Going? 24 February 2026 Cabotegravir LA for PrEP: Progress in HIV Prevention from Three Years of OPERA Data R. Hsu Poster (S-01) Who is Using Injectable PrEP, and How's That Going? 24 February 2026 Comparing PrEP coverage and HIV acquisition between CAB LA and oral PrEP in the OPERA cohort S. Barnett Poster (S-01) Who is Using Injectable PrEP, and How's That Going? 24 February 2026 EBONI M12 Results: High Real-World Effectiveness and Acceptance of CAB LA for PrEP in Black Women Z. Tims-Cook Poster (U-05) Special Populations 24 February 2026 DTG/3TC Effect of DTG/3TC vs. BIC/FTC/TAF on Steatotic Liver Disease: 96-week Analysis of PASO-DOBLE Trial J. Pineda Themed Discussion and Poster (I-02) Extra Large Challenges in Steatotic Liver Disease 24 February 2026 CD4/CD8 T Cell Telomere Length at 96 Weeks in the PASO-DOBLE Trial Comparing BIC/FTC/TAF and DTG/3TC A. Esteban-Cantos Poster (L-03) Biomarkers of Aging 24 February 2026 Transcriptomic Changes in Adipose Tissue of People with HIV on BIC/FTC/TAF or DTG/3TC Treatment P. Domingo Poster (L-01) Weight Gain and Metabolic Disorders 23 February 2026 Efficacy and safety of switching to DTG/3TC dual therapy from B/F/TAF among older adults ≥60 years L. A. Ombajo Poster (G-02) TLD and HIV Treatment in LMIC: What Are We Learning? 23 February 2026 Meta-analysis of DTG/3TC vs DTG 3DRs in ART-Naive People With High Baseline Viral Loads and Low CD4+ P. Patel Poster (G-05) Clinical Trials and Observational Studies of Antiretroviral Therapy 25 February 2026 DTG Viral Suppression with Dolutegravir-Based Regimens in Children ≤5 Years Old in Southern Africa K. Anderson Poster (P-05) Viral Suppression and Drug Resistance in Children and Adolescents With HIV 25 February 2026 VH184 Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Pro Bictegravir J. L. Jeffrey Poster (H-01) Integrase Resistance 23 February 2026 VH499 Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in people living with HIV-1 N. Thakkar Poster (F-02) Going the Distance: Pharmacokinetics of Next-Generation Long-Acting Agents 24 February 2026 About Apretude (cabotegravir long-acting) Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. Individuals must have a negative HIV-1 test prior to initiating Apretude (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. It should be used in combination with safer sex practices, such as using condoms. Apretude contains the active substance cabotegravir. Please consult the full Prescribing Information here . About Vocabria (cabotegravir) Vocabria injection is indicated - in combination with rilpivirine injection - for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the non-nucleoside reverse transcriptase inhibitors (NNRTI) and integrase inhibitor (INI) class. Vocabria tablets are indicated - in combination with rilpivirine tablets - for the short-term treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for: oral lead-in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting Vocabria injection plus long acting rilpivirine injection. oral therapy for adults who will miss planned dosing with Vocabria injection plus rilpivirine injection. Vocabria tablets are only indicated for treatment of HIV-1 in combination with rilpivirine tablets, therefore, the prescribing information for Edurant (rilpivirine) tablets should also be consulted for recommended dosing. Please consult the full Summary of Product Characteristics for all the safety information: Vocabria 400mg/600 mg prolonged-release suspension for injection and Vocabria 30 mg film-coated tablets About Rekambys (rilpivirine) Rekambys is indicated - in combination with cabotegravir injection - for the treatment of HIV-1 infection in adults and adolescents (at least 12 years of age and weighing at least 35 kg) who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class. Rekambys should always be co-administered with a cabotegravir injection. The prescribing information for cabotegravir injection should be consulted for recommended dosing. Rekambys may be initiated with oral lead-in or without (direct to injection). Please consult the full Summary of Product Characteristics for all the safety information: Rekambys 600mg/900 mg prolonged-release suspension for injection About Cabenuva (cabotegravir + rilpivirine) Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland Unlimited Company. Rilpivirine tablets are approved in the US and when used with cabotegravir is indicated for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic disease. Rilpivirine is an NNRTI that works by interfering with an enzyme called reverse transcriptase, which stops the virus from multiplying. Please consult the full Prescribing Information here . About Dovato (dolutegravir and lamivudine) Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg in the EU, and weighing at least 25kg in the US, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. Please consult the full Prescribing Information here . Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com . About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at . Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q4 Results for 2025. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY *On 20 January 2026, GSK plc and Shionogi & Co., Ltd announced that they have reached agreement together with Pfizer Inc. for the economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. Completion of the transaction is subject to certain regulatory clearances in relevant markets, and is expected to occur during the first quarter of 2026. References 1 H. Back et al. Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 2 M. Underwood et al. Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Pro Bictegravir. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 3 C.P. Rolle et al. Maintenance of HIV Suppression at 12 Months With VH3810109 (N6LS) Q4M + CAB LA QM: The EMBRACE Study. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 4 N. Thakkar et al. Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting Dosing. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 5 N. Thakkar et al. Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in people living with HIV-1. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 6 E. Castronova et al. Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 7 C. P. Rolle et al. Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 8 R.K. Hsu et al. Outcomes for Individuals who Initiate CAB+RPV LA in OPERA with Viral Loads ≥50 vs. <50 copies/mL. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 9 M. G. Sension et al. Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 10 K. Brown et al. Injection Site Reactions More Common and Bothersome with Single Doses of Lenacapavir vs Cabotegravir. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 11 R.K. Hsu et al. Cabotegravir LA for PrEP: Progress in HIV Prevention from Three Years of OPERA Data. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 12 S. Barnett et al. Comparing PrEP coverage and HIV acquisition between CAB LA and oral PrEP in the OPERA cohort. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 13 Z. Tims-Cook et al. EBONI M12 Results: High Real-World Effectiveness and Acceptance of CAB LA for PrEP in Black Women. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 14 P. Patel et al. Meta-analysis of DTG/3TC vs DTG 3DRs in ART-Naive People With High Baseline Viral Loads and Low CD4+. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 15 A. Esteban-Cantos et al. CD4/CD8 T Cell Telomere Length at 96 Weeks in the PASO-DOBLE Trial Comparing BIC/FTC/TAF and DTG/3TC. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 16 J. Pineda. Effect of DTG/3TC vs. BIC/FTC/TAF on Steatotic Liver Disease: 96-week Analysis of PASO-DOBLE Trial. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 17 P. Domingo. Transcriptomic Changes in Adipose Tissue of People with HIV on BIC/FTC/TAF or DTG/3TC Treatment. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 18 L. A. Ombajo et al. Efficacy and safety of switching to DTG/3TC dual therapy from B/F/TAF among older adults ≥60 years. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 19 A. Gaur et al. Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 20 M. Archary et al. Safety And Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Young Children 10 - <40kg. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 21 K. Anderson et al. Viral Suppression with Dolutegravir-Based Regimens in Children ≤5 Years Old in Southern Africa. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. 22 A. Turkova et al. DTG/3TC is Non-Inferior to DTG-based 3-Drug ART in Children with HIV: D3/Penta 21 Week 96 Results. Presented at the 33 rd Conference on Retroviruses and Opportunistic Infections (CROI). February 2026. Contacts ViiV Healthcare enquiries: Media: Kate Senter +44 (0) 77 9670 7446 (London) Melinda Stubbee +1 919 491 0831 (North Carolina) GSK enquiries: Media: Tim Foley +44 (0) 20 8047 5502 (London) Sarah Clements +44 (0) 20 8047 5502 (London) Kathleen Quinn +1 202 603 5003 (Washington DC) Alison Hunt +1 540 742 3391 (Washington DC) Investor Relations: Constantin Fest +44 (0) 7831 826525 (London) James Dodwell +44 (0) 20 8047 2406 (London) Mick Readey +44 (0) 7990 339653 (London) Steph Mountifield +44 (0) 7796 707505 (London) Sam Piper +44 (0) 7824 525779 (London) Jeff McLaughlin +1 215 751 7002 (Philadelphia) Frannie DeFranco +1 215 751 3126 (Philadelphia)

Phase 2Phase 1Drug ApprovalPhase 3Clinical Result

04 Feb 2026

·www.pharmaceutical-technology.com

GSK oncology and HIV drugs leads to 7% sales rise in 2025

GSK will focus on commercial launches and R&D acceleration to drive its success into 2026 and beyond. Image credit: Magda Wygralak via ShutterStock.com. GSK has posted positive sales results for fiscal year 2025 (FY2025) as the company’s new CEO, Luke Miels, takes the helm. In 2025, GSK achieved constant exchange rate (CER)-adjusted total sales of £32.7bn ($44.8bn) – up 7% from the £31.4bn achieved in 2024. Meanwhile, GSK’s core earnings per share (EPS), which excludes one-time measures was £1.72 ($2.36). The company’s market cap is currently £83.91bn ($142.6bn). During FY2025, GSK saw notable growth across its oncology portfolio, with sales income across the disease area swelling by 43% to just under £2bn ($2.7bn) compared to 2024. This forward momentum was primarily driven by a strong 89% sales increase in the company’s programmed death-1 (PD-1) inhibitor Jemperli (dostarlimab), which pulled in £861m. Myelofibrosis therapy Ojjaara/Omjjara (momelotinib) also had a robust sales growth in 2025, bringing in 60% more than the corresponding 2024 revenues with £554m in global sales. GSK’ HIV portfolio was also a key contributor to the company’s growth in 2025 – with an 11% growth compared to 2024 through a total income of £7.7bn. The company’s combination tablet, Dovato (dolutegravir/lamivudine) continued to be GSK’s best-selling HIV drug in 2025, with sales growing 22% to £2.7bn. However, the long-acting injectable therapy, Cabenuva (cabotegravir/rilpivirine), eclipsed Dovato in terms of growth, pulling in 42% more than 2024 figures with a total sales value of £1.4bn. In an investor call on 4 February, the CEO of GSK-owned ViiV Healthcare, Deborah Waterhouse, noted that these results will help offset the upcoming patent expiry of Tivicay (dolutegravir) in October 2027. While GSK has seen an uptick in its HIV portfolio in 2025, Citi analysts expect that Gilead Sciences will continue to be the market leader due to the “breadth of long-acting treatment and pre-exposure prophylaxis (PrEP) therapies in development”. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Lupus medication Benlysta (belimumab) also had a good year in 2025, with sales up 22% to $1.8bn. Meanwhile, GSK’s vaccine portfolio posted modest gains of 2%, despite waning US sales of its influenza, shingles and meningitis vaccines prompted by the Trump administration’s continued efforts to influence vaccine policy. Overall, GSK’s shingles and meningitis portfolios achieved overall growth of 8% and 12% YoY, respectively – generating £3.6bn and £1.6bn each. GSK now expects 2026 turnover growth of 3–5%. GSK’s next steps As GSK looks to 2026 and beyond, new CEO Luke Miels hopes to guide the company to success through its pipeline, which it will look to achieve through the initiation of ten pivotal trials in 2026. This includes studies for two of the company’s antibody-drug conjugate (ADC) candidates – risvutatug rezetecan and mocertatug rezetecan – which will be evaluated across multiple tumour types. GSK is also expecting five pivotal trial readouts in 2026, one of which, bepirovirsen in chronic hepatitis B, has already shown success . The company will also explore ways to maximise the launch of next-wave products, while accelerating R&D in key assets and reducing its operational complexity. As GSK seeks growth between 2028 and 2030, the company is banking on the potential HIV medications – particularly in the treatment context – which Waterhouse believes present the “biggest opportunity” to GSK’s future presence in the HIV market. Success in its HIV pipeline will be vital for GSK as it is set to be hit by patent expiries between 2027 and 2030 for dolutegravir, the compound used in Triumeq, Tivicay, and Dovato. Core patents for dolutegravir are expiring in 2027 and 2028. Dolutegravir products brought in a total of $5.65bn for GSK in 2025.

VaccineFinancial StatementDrug Approval

100 Deals associated with Dolutegravir Sodium/Lamivudine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	08 Apr 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Tuberculosis	Phase 3	Brazil	ViiV Healthcare Ltd.	18 Sep 2025
Tuberculosis	Phase 3	Brazil	ViiV Healthcare Ltd.	18 Sep 2025
HIV Seropositivity	Phase 3	United States	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Japan	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Australia	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Belgium	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Canada	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	France	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Germany	ViiV Healthcare Ltd.	18 Jan 2018
HIV Seropositivity	Phase 3	Netherlands	ViiV Healthcare Ltd.	18 Jan 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04808973 (PREGNANCY, Pubmed)	-	HIV Infections	20	拉米夫定+多替拉韦	wyryjfyrwp(ybdtzdtzbs) = wnitvdobpe fmfnnarddn (mrjdnntchj )	Positive	12 Nov 2024
NCT04585737 (DYAD, CTgov)	Phase 4	HIV Infections	222	Dolutegravir / Lamivudine Pill (Treatment Group 1)	acemzhuopr = voyatbaqlf qdkoczssoe (ktjyyanypt, yejxtrlrtw - qtvmicduyj) View more	-	17 Oct 2024
				Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill (Treatment Group 2)	acemzhuopr = xpeyndziub qdkoczssoe (ktjyyanypt, tynrpyrmoh - yocsmicndx) View more
PASO DOBLE (NEWS) Manual	Phase 4	HIV Infections Maintenance	-	Dovato (dolutegravir/lamivudine)	uiazyuhgdi(louvfdxeom) = Dovato demonstrating non-inferior efficacy in maintaining viral suppression after 48 weeks of treatment compared to Biktarvy. erwskxxytj (anjdiwcogg ) Met	Non-inferior	24 Jul 2024
				Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
NCT03446573 (TANGO, Pubmed \| Antimicrob Agents Chemother) Manual	Phase 3	HIV Infections	362	Dolutegravir/lamivudine FDC	wkrldxnnnx(gsxvsneioh) = clkgiullik hzbakxbcsl (lcmqximhag ) View more	Positive	08 Apr 2024
NCT04707326 (DUALING, Pubmed \| Open Forum Infect Dis) Manual	Not Applicable	HIV Infections	2,040	Dolutegravir/lamivudine	hygwdcpvyb(ccbljptvfz) = pfajbjukdf vgpnvojrzl (wbnogaqygc ) View more	Positive	01 Apr 2024
				Continuing triple-drug antiretroviral regimens	hygwdcpvyb(ccbljptvfz) = lpbrnegwat vgpnvojrzl (wbnogaqygc ) View more
NCT04021290 \| NCT03446573 (SALSA, Pubmed) Manual	Phase 3	HIV Infections	1,234	Switch to dolutegravir/lamivudine (DTG/3TC)	hilmwpnsfz(bexkmajtgd) = In the DTG/3TC group, incidence of adverse events (AEs) was similar across age groups. ppdmehjffy (phmwvchgpd ) View more	Positive	21 Mar 2024
				Continuing current antiretroviral regimen (CAR)
NCT04827134 (CTgov)	Phase 1	HIV Infections	33	TRIUMEQ+DTG+ABC+3TC (Cohort 1: TRIUMEQ (DTG/ABC/3TC) Fed)	lunyzkbusn(ouihcvgihs) = ovjyygdvxi jvyegjwofv (czkmzuzcfx, 25.7) View more	-	05 Jun 2023
				DTG+ABC+3TC (Cohort 1: TRIUMEQ (DTG/ABC/3TC) Fasted)	lunyzkbusn(ouihcvgihs) = zrkghgzmax jvyegjwofv (czkmzuzcfx, 24.0) View more
NCT03682848 (CTgov)	Phase 3	HIV Infections	32	DTG + 3TC FDC	tfzmokkevb = blufezofvv mmmwjayrzu (xweaybtofu, kkzngulaak - xnaybseicl) View more	-	08 Aug 2022
NCT04021290 (SALSA, CTgov)	Phase 3	HIV Infections	493	3TC FDC+DTG (Randomized Phase-Participants Who Received DTG/3TC FDC)	rnoecllrlf = bpmhwgcvwn qcsxahumdd (klfojdgwuh, aapyhnjfgu - jwjndqsdnb) View more	-	01 Jul 2022
				atazanavir (Randomized Phase-Participants Who Received CAR)	rnoecllrlf = bfvrijpxou qcsxahumdd (klfojdgwuh, zvtisimfwa - tukoqruing) View more
IAS2022	Not Applicable	-	-	Dolutegravir/Lamivudine (D/L)	sxpjiyrhbn(xysxtwjoqc) = tbwqtksjjo uiwzfpuuwt (mfwgtionem ) View more	-	01 Jan 2022
				Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/T)	sxpjiyrhbn(xysxtwjoqc) = aswvpbzcbk uiwzfpuuwt (mfwgtionem ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis